CD33 and acute myeloid leukemia: Perna et al. used large surface genome datasets from malignant (AML) and normal tissues and found CD123, CLEC12A, and CD33 to be highly expressed on AML blasts at >75% expression but also with high expression on normal hematopoietic stem cells with the possibility of introducing many side effects in patients [37].